

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No:

10/751,611

Applicants:

Derek Wyndham Clissold et al.

Filed:

January 5, 2004

Title:

PROSTAGLANDIN SYNTHESIS

TC/A.U.:

1621

Examiner:

INFORMATION DISCLOSURE STATEMENT

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 (RP) submitted herewith. A copy of each of the listed references, except for the listed U.S. patent, is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

The Japanese references, Nos. 1-228933, 60-166639, 59-44336 and 57-171965, are not in the English language, but English abstracts thereof are attached to each copy of the references submitted herewith. Also, these references were cited by a foreign patent office in a counterpart foreign application. A copy of this English language search report, indicating the degree of relevance determined by the foreign patent office is submitted herewith. MPEP Section 609A(3), second paragraph.

The Chinese reference entitled "Synthesis of the Antiglaucoma Drug Latanoprost and its Effect on Reduction of Intraocular Pressure (IOP)" is not in the English language, but an English abstract thereof is attached to the copy of the reference submitted herewith. Also, the

JMYT-314US PATENT

applicants refer the Examiner to the synthetic scheme on pages 213 and 214, which does not require translation.

This Information Disclosure Statement is being filed before mailing of the first Official Action. No first Official Action has yet been received and it is presumed that none has yet been mailed. No fee or statement is required. 37 C.F.R. § 1.97(b).

Respectfully submitted,

Christopher R. Lewis, Reg. No. 36,201

Attorney for Applicants

CRL/Irb

Enclosures: Forms PTO/SB/08A (1 pg.) and

PTO/SB/08B (1 pg.) Copy of ten (10) references Copy of British Search Report

Dated: July 9, 2004

P.O. Box 980 Valley Forge, PA 19482-0980 (610) 407-0700

The Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. **18-0350** of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

July 9, 2004

Date

Christopher R. Lewis

LRB_I:\JMYT\314US\IDS-001.DOC

Substitute for Form 1449A/PTO		Complete if Known	
	Application Number	10/751,611	
INFORMATION DISCLOSURE	Filing Date	January 5, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Derek Wyndham Clissold	
	Art Unit	1621	
(1)	Examiner Name		
SHEET 1 of 2	Attorney Docket No.	JMYT-314US	
2004 (8.1			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Number - Kind Code ^{2 (if known)}	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
THUGIS				Nelson	/ igui co / ippedi
	1	US-3,920,723	11-18-1975	Nelson	
		US-			
	<u> </u>	US-			
		US-			
		US-			
	1	US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ^{5 (If known)}	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
	2	EP-0 178 139-A3	04-16-1986	Teijin Limited	i vigoros rippus	$\overline{}$
	3	GB-1 582 853	01-14-1981	Imperial Chemical Industries Limited		┌─
	4	JP-1-228933	09-12-1989	Fumie Satao		
	5	JP-60-166639	08-29-1985	Sagami Chuo Kagaku Kenkyusho		
	6	JP-59-44336	03-12-1984	Teijin Limited		
	7	JP-57-171965	10-22-1982	Teijin Limited		
	8	WO-02/096868	12-05-2002	Finetech Laboratories Ltd.		
	9	WO-02/090324	11-14-2002	Yonsung Fine Chemical Co.		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Applicant's unique citation designation number (optional).

²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

^{*}Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

*Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for Form 1449B/PTO	Complete if Known		
	Application Number	10/751,611	
INFORMATION DISCLOSURE	Filing Date	January 5, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Derek Wyndham Clissold	
(Use applicancy sheets as necessary)	Art Unit	1621	
(0, '' '')	Examiner Name		
3 7004 SHEET 2 of 2	Attorney Docket No.	JMYT-314US	

	JOL ,		
<i>\rak{k}</i>	ET L	NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	10	Paul W. Collins and Stevan W. Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs," Chem. Rev., 1993, Vol. 4, pp. 1533-1564.	
	11	Chen Jianxing, Chen Hailin, and Chen Liangkang, "Synthesis of the Antiglaucoma Drug Latanoprost and its Effect on Reduction of Intraocular Pressure (IOP)," Chinese Journal of Medicinal Chemistry, September 1988, Vol. 8, No. 3, pp. 213-217.	
	12	British Search Report dated May 4, 2004, from British Application No. 0329379.2.	
·····			
:			
			<u> </u>
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.